Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1998;82:1016-1020

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oberle, S.
Right arrow Articles by Schröder, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oberle, S.
Right arrow Articles by Schröder, H.
(Circulation Research. 1998;82:1016-1020.)
© 1998 American Heart Association, Inc.


Rapid Communications

Aspirin Increases Ferritin Synthesis in Endothelial Cells

A Novel Antioxidant Pathway

Stefanie Oberle, Tobias Polte, Aida Abate, Hans-Peter Podhaisky, , Henning Schröder

From the Department of Pharmacology and Toxicology, School of Pharmacy, Martin Luther University, Halle (Saale), Germany.

Correspondence to Dr Henning Schröder, School of Pharmacy, Martin Luther University, Wolfgang-Langenbeck-Str. 4, 06099 Halle (Saale), Germany. E-mail schroeder{at}pharmazie.uni-halle.de


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Aspirin has recently been shown to increase endothelial resistance to oxidative damage. However, the mechanism underlying aspirin-induced cytoprotection is still unknown. Using cultured cells, the present study investigates the effect of aspirin on the expression of ferritin, a cytoprotective protein that sequesters free cytosolic iron, the main catalyst of oxygen radical formation. In bovine pulmonary artery endothelial cells, aspirin at low antithrombotic concentrations (0.03 to 0.3 mmol/L) induced the synthesis of ferritin protein in a time- and concentration-dependent fashion up to 5-fold over basal levels, whereas ferritin H (heavy chain) mRNA remained unaltered. Aspirin-induced cytoprotection from hydrogen peroxide toxicity was mimicked by exogenous iron-free apoferritin but not iron-loaded ferritin, demonstrating the antioxidant function of newly synthesized ferritin under these conditions. Ferritin induction by aspirin was specific in that other nonsteroidal anti-inflammatory drugs such as salicylic acid, indomethacin, or diclofenac failed to alter ferritin protein levels. Aspirin-induced ferritin synthesis was abrogated in the presence of the iron chelator desferrioxamine, pointing to an interaction of aspirin with iron-responsive activation of ferritin translation. Together, our results suggest induction of ferritin as a novel mechanism by which aspirin may prevent endothelial injury in cardiovascular disease, eg, during atherogenesis.


Key Words: aspirin • ferritin • endothelial cell • gene expression • antioxidant defense mechanism


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Aspirin is known to reduce the incidence of thrombotic occlusive events such as myocardial infarction and stroke.1 This effect is considered to be due to the platelet inhibitory action of aspirin, which results from irreversible inhibition of platelet cyclooxygenase activity and thromboxane formation.2 Thromboxane is a potent agonist and crucial mediator of vascular smooth muscle contraction and platelet aggregation.3 Recently, however, a more direct effect of aspirin on the integrity of the vascular wall has been reported in studies involving the antioxidant properties of aspirin and the capacity of aspirin to protect endothelial cells from the deleterious effects of hydrogen peroxide and, in particular, from iron-dependent oxygen radical formation.4 5 6

The mechanism responsible for the observed aspirin-induced endothelial protection is unknown. From the data published by Podhaisky et al,6 it appears that cytoprotection by aspirin is a long-term effect that occurs after several hours of pretreatment. Therefore, a possible mechanism might be the induction of genes that protect cells from damage by reactive oxygen species. In recent studies, the induction of ferritin has been shown to provide marked antioxidant cellular protection by rapidly sequestering free cytosolic iron, the crucial catalyst of oxygen-centered radical formation via the Fenton reaction in biological systems.7 8 Thus, ferritin, which until then was thought to function merely as a "housekeeper" iron storage protein, has emerged as a critical and fast-acting endogenous cytoprotectant that plays an important role in cellular antioxidant defense mechanisms.9 10 Our aim, therefore, was to investigate whether ferritin is a potential site of action for aspirin and to characterize the effect of aspirin on the expression of ferritin in endothelial cells.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Materials
Bovine pulmonary artery endothelial cells (ATCC CCL 209) were obtained from the American Type Culture Collection. FBS, DMEM, and penicillin/streptomycin were obtained from GIBCO. Hydrogen peroxide was from Merck. The RNeasy Total RNA-Kit was from Qiagen. The DIG DNA Labeling and Detection Kit, the Chemiluminescence Western Blotting Kit, and ß-actin cDNA were from Boehringer Mannheim. The 530-bp PstI ferritin H (heavy chain) cDNA fragment was a kind gift from Dr Gaetano Cairo (Centro di Studio sulla Patologia Cellulare, CNR, Milano, Italy).8 Apoferritin and all other chemicals were bought from Sigma.

Cell Culture
Endothelial cells were maintained and subcultured in DMEM supplemented with 15% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin.11 The cells were grown in a humidified incubator at 37°C and 5% CO2.

Ferritin mRNA Analysis
Ferritin mRNA content was analyzed in endothelial cells grown in 150-mm culture dishes after treatment with control media or aspirin for 6 hours. Total RNA was isolated with the RNeasy Total RNA Kit. RNA (40 µg) from each sample was denatured and fractionated by 1% agarose-formaldehyde gel electrophoresis. RNA was visualized by ethidium bromide staining, transferred to nylon membranes, and baked for 0.5 hours at 120°C. The membranes were hybridized with a random-primed digoxigenin-labeled cDNA probe for human ferritin H8 or for ß-actin according to the DIG System user's guide (Boehringer Mannheim). Afterward, membranes were incubated with the chemiluminescent substrate CSPD (Boehringer Mannheim) and exposed to x-ray film for 2 hours. Equal loading of each lane with RNA was assessed by staining 18S and 28S rRNA with ethidium bromide and by using ß-actin cDNA. Autoradiographs were quantified by computer-assisted videodensitometry (Eagle Eye II-system, Stratagene). Autoradiograms were scanned by densitometry, and the results were normalized to the ratio of ferritin/ß-actin hybridization seen in control (untreated) cells.

Ferritin Protein Analysis
Endothelial cells were cultured in 6-well plates as described above. After a 6-hour incubation with control media, aspirin, salicylic acid, diclofenac, or indomethacin, cells were washed and extracted as described previously.12 13 Desferrioxamine was added to the cells 30 minutes before aspirin. Protein (100 µg) was applied to SDS-PAGE. After electrophoresis, protein was transferred to a nitrocellulose membrane, and a polyclonal antibody to human ferritin (Sigma) was used to identify ferritin protein content. Antigen-antibody complexes were visualized with the horseradish peroxidase chemiluminescence system according to the manufacturer's instructions (Boehringer Mannheim). Quantification of ferritin induction was performed using computer-assisted videodensitometry (Eagle Eye II-system, Stratagene).

Cell Viability Analysis
Endothelial cells were seeded at 2x104 cells per well in 96-well microtiter plates in 100 µL of media containing 15% FBS. After a 48-hour incubation at 37°C, cells reached confluence, and aspirin, apoferritin, or ferritin was added. After a 6-hour incubation, hydrogen peroxide was added to the cells. Incubation was continued for 20 hours, followed by a cytotoxicity assay. Cell viability was measured by staining with crystal violet as previously described.14 15 16 This colorimetric test allows assessment of the remaining viable cells after the incubation procedure. After they were washed with PBS, cells were fixed with methanol for 10 minutes and then stained for 10 minutes with a 0.1% crystal violet solution. After 3 washes with tap water, the dye was eluted with 0.1 mol/L trisodium citrate in 50% ethanol for 10 minutes. Optical density at 630 nm was measured using a microtiter plate reader (Biotek EL 311s).


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Aspirin increased ferritin protein synthesis in a concentration-dependent fashion: 2.4±0.3 (0.03 mmol/L aspirin), 3.6±0.4 (0.1 mmol/L aspirin), and 4.0±0.3 (0.3 mmol/L aspirin) (significant for all values: P<0.05 for aspirin versus control, 2-tailed t test). The densitometric data are mean±SEM of 3 independent experiments and represent fold induction versus control (untreated) cells. A representative experiment is shown in Figure 1ADown. However, mRNA levels of ferritin H remained unaltered in the presence of aspirin (Figure 1BDown). Induction of ferritin protein levels by aspirin (0.3 mmol/L) was time dependent: 1.7±0.2 (4 hours), 3.5±0.3 (6 hours), 3.9±0.4 (8 hours), and 4.6±0.3 (10 hours) (significant for all values: P<0.05 for aspirin versus control, 2-tailed t test). The densitometric data are mean±SEM of 3 independent experiments and represent fold induction versus control (untreated) cells. A representative experiment is shown in Figure 2ADown. Over the entire time course assessed, aspirin had no effect on ferritin H mRNA (Figure 2BDown). Ferritin protein induction by aspirin was specific in that other nonsteroidal anti-inflammatory drugs, such as salicylic acid, indomethacin, or diclofenac, failed to alter ferritin protein levels (Figure 3Down). In the presence of the iron chelator desferrioxamine, aspirin-enhanced ferritin synthesis was abrogated: 3.4±0.3 (0.3 mmol/L aspirin) (P<0.05 for treatment versus control, 2-tailed t test), 0.9±0.1 (0.3 mmol/L aspirin+0.1 mmol/L desferrioxamine) (P=NS), and 0.9±0.2 (0.1 mmol/L desferrioxamine) (P=NS). The densitometric data are mean±SEM of 3 independent experiments and represent fold induction versus control (untreated) cells. A representative experiment is shown in Figure 4Down. Preincubating the cells for 6 hours with iron-free apoferritin (1 mg/mL) but not with iron-loaded ferritin (1 mg/mL) reduced hydrogen peroxide–mediated cytotoxicity by 50%, thus mimicking a similar antioxidant effect of aspirin (0.03 mmol/L, toxicity reduction by 57%) under these conditions (Figure 5Down). Apoferritin, ferritin, or aspirin alone had no significant effect on endothelial cell viability.



View larger version (37K):
[in this window]
[in a new window]
 
Figure 1. Effect of aspirin (ASA) on ferritin protein expression (A) and mRNA levels (B) of ferritin heavy chain (ferritin H) in endothelial cells. Cells were incubated for 6 hours in the presence or absence (CON) of aspirin at the concentrations indicated. Protein isolation, Western blot analysis, RNA isolation, and Northern blot analysis were performed as described in "Materials and Methods." The data are representative of 3 separate experiments with similar results.



View larger version (41K):
[in this window]
[in a new window]
 
Figure 2. Time-dependent effect of aspirin (ASA) on ferritin protein expression (A) and mRNA levels (B) of ferritin heavy chain (ferritin H) in endothelial cells. Incubations, protein isolation, Western blot analysis, RNA isolation, and Northern blot analysis were performed as described in "Materials and Methods." The data shown are from 1 representative experiment that was performed 3 times with similar results. CON indicates control (absence of aspirin).



View larger version (11K):
[in this window]
[in a new window]
 
Figure 3. Effect of aspirin (ASA), salicylic acid (SA), diclofenac (DIC), and indomethacin (IND) on ferritin protein levels in endothelial cells. Incubations and ferritin protein analysis were carried out as described in "Materials and Methods." The densitometric data shown are mean±SEM of 3 separate experiments. *P<0.05 for treatment vs control (CON), 2-tailed t test.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 4. Effect of desferrioxamine (Des) on aspirin (ASA)-induced ferritin protein synthesis in endothelial cells. Incubations and ferritin protein analysis were carried out as described in "Materials and Methods." The data shown are from 1 representative experiment that was performed 3 times with similar results. CON indicates control.



View larger version (13K):
[in this window]
[in a new window]
 
Figure 5. Effect of apoferritin (APO), ferritin (FER), and aspirin (ASA) on hydrogen peroxide (H2O2)-mediated cytotoxicity in endothelial cells. Incubations were carried out as described in "Materials and Methods." *P<0.05 for treatment versus control (CON), 2-tailed t test. All data shown are mean±SEM of 6 independent observations in separate cell culture wells. The experiment was performed 3 times with similar results using endothelial cell cultures at different passages.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
The present study demonstrates, for the first time, that aspirin induces the synthesis of the antioxidant defense protein ferritin. Ferritin, in addition to serving as an iron reserve for the maintenance of vital cellular functions, sequesters iron that might otherwise catalyze damaging oxidative reactions. This cytoprotective antioxidant role of ferritin has remained largely hypothetical until it was shown that cells overexpressing this protein are more resistant to oxidative injury,7 10 13 whereas organisms lacking a functional ferritin gene are more sensitive to oxidative stress.17

Using cultured endothelial cells, we observed ferritin induction by aspirin at therapeutically relevant concentrations being achieved in plasma during low-dose antithrombotic dosing regimens.18 19 Earlier studies have reported inhibitory effects of aspirin on nuclear factor-{kappa}B (NF-{kappa}B, a transcription factor)20 21 22 and on the regulation of genes such as nitric oxide synthase23 24 but only at rather high concentrations (2 to 20 mmol/L), which are hardly reached or maintained in plasma even after anti-inflammatory doses of aspirin. Therefore, and in contrast to NF-{kappa}B or NO synthase, ferritin appears to be a molecular target of aspirin with a particular potential for clinical significance. Moreover, ferritin induction by aspirin might explain earlier observations showing that aspirin is capable of directly protecting cultured endothelial cells from oxidant injury.6 Interestingly, aspirin-dependent endothelial protection reported by Podhaisky et al6 was most pronounced when toxicity was induced by exogenous ferrous iron, the main Fenton catalyst of oxygen radical formation in living cells. From the results of the present investigation, it seems plausible that by increasing the synthesis of iron-scavenging ferritin, aspirin may specifically withdraw iron ions from the site of oxygen radical formation and may thus effectively interrupt the reaction cascade leading to oxidative stress and tissue damage. Further support for this hypothesis may be derived from our observation that exogenous iron-free apoferritin but not iron-loaded ferritin reduced hydrogen peroxide–mediated injury in endothelial cells, thus mimicking the protective action of aspirin and demonstrating the antioxidant function of newly synthesized ferritin under these conditions.

According to our results, the stimulatory effect of aspirin on the expression of ferritin is confined to the translational level. No detectable increase in ferritin mRNA was measured in the presence of aspirin. The main physiological stimulus of ferritin protein synthesis is known to be free intracellular iron, which binds to and inactivates the endogenous repressor of ferritin translation, the iron regulatory protein.25 To determine whether aspirin induction of ferritin is related to this pathway or occurs independent of free iron, we performed experiments using the iron chelator desferrioxamine. Coincubation with desferrioxamine completely abolished ferritin induction by aspirin, suggesting that free cytosolic iron is required for this effect and that aspirin increases ferritin synthesis by interacting with and possibly activating the well-known iron-dependent posttranscriptional upregulation of ferritin.25 Interestingly, the ferritin-inducing effect we report here is specific for aspirin and not elicited by other nonsteroidal anti-inflammatory drugs, such as diclofenac, indomethacin, or salicylate. This finding implies that it is the acetyl group within acetylsalicylic acid that confers the capacity to activate ferritin synthesis and that all other inhibitors of cyclooxygenase tested, including nonacetylated salicylate, do not fulfill the structural requirements necessary to activate ferritin translation. Aspirin has been demonstrated to specifically interact with and show affinity toward iron or iron complexes,6 26 and it is therefore conceivable that aspirin accelerates dissociation of the ferritin repressor protein from ferritin mRNA, thus allowing ferritin translation. Clearly, more research is needed in order to further analyze the molecular mechanisms by which aspirin exerts its ferritin-inducing effect.

On the basis of the outcome of recent clinical studies, an increase in cellular iron levels has been suggested as a coronary risk factor that (via enhancing oxidative stress) promotes atherosclerosis and raises the incidence of myocardial infarction.27 28 29 30 Moreover, elevation of catalytically active iron followed by increased expression of ferritin has been observed in atherosclerotic lesions of patients with coronary heart disease, underlining the in vivo relevance of this antioxidant pathway.9 31 32 There has been dispute about the availability in vivo of uncomplexed iron as a Fenton catalyst for redox-based reactions that induce oxidative stress, and the nature of the pool of nonprotein-bound iron in cells and organelles is ill-defined.33 34 However, recent progress in analytical methods has made possible the detection and quantification of nonprotein-bound iron in biological tissues and fluids, including those of human origin, thus confirming the existence of catalytically active ferrous iron in vivo.35 36 Other in vivo evidence for the relevance of free or loosely bound iron in promoting damage by radical formation comes from studies showing beneficial and tissue protective effects of metal-chelating agents such as desferrioxamine under pathological conditions involving oxidative stress.37 38 In light of our investigations, activation of endogenous iron sequestration could be an important mechanism by which aspirin, in addition to its platelet inhibitory action, protects against myocardial infarction, stroke, and death. Since ferritin is thought to play a broader role in the cellular defense against oxidative injury under inflammatory conditions,9 it is conceivable that increased ferritin expression may also contribute in general to the anti-inflammatory action of aspirin.

In summary, we have demonstrated for the first time that aspirin at therapeutically relevant concentrations is capable of activating the synthesis of ferritin, a protein with cytoprotective and antioxidant properties. Although, on the molecular level, aspirin appeared to enhance iron-dependent ferritin translation, the exact mechanism of aspirin-dependent ferritin induction is not yet fully understood and is currently being investigated in our laboratory. However, with regard to the functional consequences and considering the comparatively low aspirin concentrations required to trigger ferritin synthesis, it can be concluded that this novel antioxidant pathway may significantly contribute to aspirin-induced prevention of endothelial injury in cardiovascular disease, eg, during atherogenesis and other inflammatory processes.


*    Acknowledgments
 
This study was supported by the Deutsche Forschungsgemeinschaft (Schr 298/8-1+2). We would like to thank Petra Schwartz and Martina Heidler for excellent technical and secretarial assistance, respectively.

Received February 2, 1998; accepted March 26, 1998.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 

  1. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659–675.[Free Full Text]
  2. Samuelsson B, Granström E, Green K, Hamberg M, Hammarström S. Prostaglandins. Annu Rev Biochem. 1975;44:669–695.[Medline] [Order article via Infotrieve]
  3. Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs. 1988;35:154–176.
  4. Aruoma OI, Halliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 1988;18:459–470.[Medline] [Order article via Infotrieve]
  5. Woollard AC, Wolff SP, Bascal ZA. Antioxidant characteristics of some potential anticataract agents: studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic Biol Med. 1990;9:299–305.[Medline] [Order article via Infotrieve]
  6. Podhaisky HP, Abate A, Polte T, Oberle S, Schröder H. Aspirin protects endothelial cells from oxidative stress: possible synergism with vitamin E. FEBS Lett. 1997;417:349–351.[Medline] [Order article via Infotrieve]
  7. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992;267:18148–18153.[Abstract/Free Full Text]
  8. Cairo G, Tacchini L, Pogliaghi G, Anzon E, Tomasi A, Bernelli-Zazzera A. Induction of ferritin synthesis by oxidative stress. J Biol Chem. 1995;270:700–703.[Abstract/Free Full Text]
  9. Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am J Pathol. 1995;147:782–789.[Abstract]
  10. Kim YM, Bergonia H, Lancaster JR. Nitrogen oxide-induced autoprotection in isolated rat hepatocytes. FEBS Lett. 1995;374:228–232.[Medline] [Order article via Infotrieve]
  11. Schröder H, Warren S, Bargetzi MJ, Torti SV, Torti FM. N-Acetyl-L-cysteine protects endothelial cells but not L929 tumor cells from tumor necrosis factor-{alpha}-mediated cytotoxicity. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:664–666.[Medline] [Order article via Infotrieve]
  12. Akarasereenont P, Mitchell JA, Appelton I, Thiemermann C, Vane JR. Involvement of tyrosine kinase in the induction of cyclooxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol. 1994;113:1522–1528.[Medline] [Order article via Infotrieve]
  13. Oberle S, Schröder H. Ferritin may mediate SIN-1-induced protection against oxidative stress. Nitric Oxide Biol Chem (Arch Biochem Biophys B). 1997;1:308–314.
  14. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984;68:167–175.[Medline] [Order article via Infotrieve]
  15. Polte T, Oberle S, Schröder H. The nitric oxide donor SIN-1 protects endothelial cells from tumor necrosis factor-{alpha}-mediated cytotoxicity: possible role for cyclic GMP and heme oxygenase. J Mol Cell Cardiol. 1997;29:3305–3310.[Medline] [Order article via Infotrieve]
  16. Wink DA, Cook JA, Pacelli R, DeGraff W, Gamson J, Liebmann J, Krishna MC, Mitchell JB. The effect of various nitric oxide-donor agents on hydrogen peroxide-mediated toxicity: a direct correlation between nitric oxide formation and protection. Arch Biochem Biophys. 1996;331:241–248.[Medline] [Order article via Infotrieve]
  17. Wai SN, Nakayama K, Umene K, Moriya T, Amako K. Construction of a ferritin-deficient mutant of Campylobacter jejuni: contribution of ferritin to iron storage and protection against oxidative stress. Mol Microbiol. 1996;20:1127–1134.[Medline] [Order article via Infotrieve]
  18. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989;10:453–458.[Medline] [Order article via Infotrieve]
  19. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137–1141.[Abstract]
  20. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–959.[Abstract/Free Full Text]
  21. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91:1914–1917.[Abstract/Free Full Text]
  22. Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S. Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages. Mol Pharmacol. 1997;52:421–429.[Abstract/Free Full Text]
  23. Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissmann G, Abramson SB. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A. 1995;92:7926–7930.[Abstract/Free Full Text]
  24. Kwon G, Hill JR, Corbett JA, McDaniel ML. Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Pharmacol. 1997;52:398–405.[Abstract/Free Full Text]
  25. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996;1275:161–203.[Medline] [Order article via Infotrieve]
  26. Schwarz KB, Arey BJ, Tolman K, Mahanty S. Iron chelation as a possible mechanism for aspirin-induced malondialdehyde production by mouse liver microsomes and mitochondria. J Clin Invest. 1988;81:165–170.
  27. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86:803–811.[Abstract/Free Full Text]
  28. Sullivan JL. Stored iron and ischemic heart disease: empirical support for a new paradigm. Circulation. 1992;86:1036–1037.[Free Full Text]
  29. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, Spogler F, Jarosch E, Oberhollenzer F, Willeit J. Body iron stores and presence of carotid atherosclerosis: results from the Bruneck study. Arterioscler Thromb. 1994;14:1625–1630.[Abstract/Free Full Text]
  30. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997;314:793–794.[Free Full Text]
  31. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:803–811.
  32. Pang JHS, Jiang MJ, Chen YL, Wang FW, Wang DL, Chu SH, Chau LY. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest. 1996;97:2204–2212.[Medline] [Order article via Infotrieve]
  33. Crichton RR, Charloteaux-Wauters M. Iron transport and storage. Eur J Biochem. 1987;164:485–506.[Medline] [Order article via Infotrieve]
  34. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford, UK: Clarendon Press; 1989.
  35. Brieland JK, Clarke SJ, Karmiol S, Phan SH, Fantone JC. Transferrin: a potential source of iron for oxygen free radical-mediated endothelial cell injury. Arch Biochem Biophys. 1992;294:265–270.[Medline] [Order article via Infotrieve]
  36. Kawasaki N, Tanimoto T, Tanaka A, Hayakawa T, Miyasaka N. Determination of non-protein-bound iron in human synovial fluid by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1994;656:436–440.[Medline] [Order article via Infotrieve]
  37. Paller MS, Hedlund BE. Role of iron in postischemic renal injury in the rat. Kidney Int. 1988;34:474–480.[Medline] [Order article via Infotrieve]
  38. Kadiiska MB, Burkitt MJ, Xiang QH, Mason RP. Iron supplementation generates hydroxyl radical in vivo: an ESR spin-trapping investigation. J Clin Invest. 1995;96:1653–1657.



This article has been cited by other articles:


Home page
J. Nutr.Home page
K. Erdmann, N. Grosser, K. Schipporeit, and H. Schroder
The ACE Inhibitory Dipeptide Met-Tyr Diminishes Free Radical Formation in Human Endothelial Cells via Induction of Heme Oxygenase-1 and Ferritin
J. Nutr., August 1, 2006; 136(8): 2148 - 2152.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Kojda
Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?
Cardiovasc Res, November 1, 2004; 64(2): 192 - 194.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
J.L. Mehta, J. Chen, F. Yu, and D.Y. Li
Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells
Cardiovasc Res, November 1, 2004; 64(2): 243 - 249.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
S. M Wasserman and J. N Topper
Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implications
Vascular Medicine, February 1, 2004; 9(1): 35 - 45.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Grosser and H. Schroder
Aspirin Protects Endothelial Cells From Oxidant Damage Via the Nitric Oxide-cGMP Pathway
Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1345 - 1351.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
S. Oberle, A. Abate, N. Grosser, A. Hemmerle, H. J. Vreman, P. A. Dennery, H. T. Schneider, D. Stalleicken, and H. Schroder
Endothelial Protection by Pentaerithrityl Trinitrate: Bilirubin and Carbon Monoxide as Possible Mediators
Experimental Biology and Medicine, May 1, 2003; 228(5): 529 - 534.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
K. Prasad and P. Lee
Suppression of Oxidative Stress as a Mechanism of Reduction of Hypercholesterolemic Atherosclerosis by Aspirin
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 61 - 69.
[Abstract] [PDF]


Home page
StrokeHome page
J. De Cristobal, A. Cardenas, I. Lizasoain, J. C. Leza, P. Fernandez-Tome, P. Lorenzo, and M. A. Moro
Inhibition of Glutamate Release via Recovery of ATP Levels Accounts for a Neuroprotective Effect of Aspirin in Rat Cortical Neurons Exposed to Oxygen-Glucose Deprivation
Stroke, January 1, 2002; 33(1): 261 - 267.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Polte, A. Abate, P. A. Dennery, and H. Schroder
Heme Oxygenase-1 Is a cGMP-Inducible Endothelial Protein and Mediates the Cytoprotective Action of Nitric Oxide
Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1209 - 1215.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Talbodec, N. Berkane, V. Blandin, J. P. Breittmayer, E. Ferrari, C. Frelin, and P. Vigne
Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism
Mol. Pharmacol., April 1, 2000; 57(4): 797 - 804.
[Abstract] [Full Text]


Home page
ChestHome page
T. Stefanec
Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease?
Chest, March 1, 2000; 117(3): 841 - 854.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Kagawa, H. Azuma, M. Akaike, Y. Kanagawa, and T. Matsumoto
Aspirin Reduces Apolipoprotein(a) (Apo(a)) Production in Human Hepatocytes by Suppression of Apo(a) Gene Transcription
J. Biol. Chem., November 26, 1999; 274(48): 34111 - 34115.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. L. Hickenbottom, J. C. Grotta, R. Strong, L. A. Denner, J. Aronowski, and R. L. Macdonald
Nuclear Factor-{kappa}B and Cell Death After Experimental Intracerebral Hemorrhage in Rats • Editorial Comment
Stroke, November 1, 1999; 30 (11): 2472 - 2478.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Stefanec
Circulating Apoptotic Endothelial Cells
Blood, August 15, 1999; 94(4): 1482 - 1483.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
B. de Valk and J. J. M. Marx
Iron, Atherosclerosis, and Ischemic Heart Disease
Arch Intern Med, July 26, 1999; 159(14): 1542 - 1548.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. S. Wolin
Novel Antioxidant Action of Aspirin May Contribute to Its Beneficial Cardiovascular Actions
Circ. Res., May 19, 1998; 82(9): 1021 - 1022.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oberle, S.
Right arrow Articles by Schröder, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oberle, S.
Right arrow Articles by Schröder, H.